Guidelines for the application of zotuximab (Vyloy) in the treatment of gastric cancer and gastro-esophageal cancer

Stomach The esophageal junction, as a key part connecting the esophagus and stomach, plays an important role in the digestive system. However, malignant lesions sometimes occur in this area and its adjacent tissues. In response to such situations, Zolbetuximab (Vyloy, also known as Zolbetuximab), as a cutting-edge monoclonal antibody therapy, has opened up new treatment avenues for patients with specific types of gastric cancer or gastro-esophageal cancer.

Zotuximab can accurately identify and adhere closely to the surface of cancer cells expressing "CLDN18.2" antigen, and subsequently triggers a series of biological effects to effectively destroy these malignant cells. This unique mechanism of action makes zotuximab particularly suitable for patients with "CLDN18.2"-positive and "human epidermal growth factor receptor 2 (HER2)"-negative gastric cancer or gastro-esophageal cancer, especially when the tumor is unresectable or has distant metastasis.

In clinical applications, zotuximab is often used in combination with other anticancer drugs to exert a synergistic therapeutic effect. This combined strategy aims to jointly attack cancer cells through different mechanisms of action, thereby improving the therapeutic effect and prolonging the survival of patients.

Regarding the administration method of zotuximab, it is administered through intravenous injection, that is, the drug solution is slowly dripped directly into the intravenous blood vessels. This process needs to be carried out under the guidance of a doctor with extensive experience in cancer treatment, and the time of each infusion must be no less than 2 hours to ensure that the drug can fully enter the blood circulation and reach an effective therapeutic concentration.

As for the specific dosage and treatment cycle, they need to be comprehensively determined based on the patient's individual situation, severity of the disease, and other anti-cancer drugs used in combination. Generally speaking, patients will follow a personalized treatment plan prescribed by their doctor and receive zotuximab every 2 to 3 weeks. During the treatment period, the doctor will closely monitor the patient's physical condition and disease changes, and adjust the treatment plan as needed.

It is important to note that although zotuximab is an effective anti-cancer drug, it can also cause some serious side effects. Therefore, patients should always remain vigilant and pay close attention to their physical condition during treatment. Once any discomfort or abnormal reaction occurs, you should report it to your doctor immediately so that timely response measures can be taken.

In short, zotuximab (Vyloy) is a monoclonal antibody therapy targeting specific types of gastric cancer or gastro-esophageal cancer. Its usage and dosage must strictly follow the guidance of professional doctors and be personalized based on the actual situation of the patient. During the treatment process, patients should maintain close communication with their doctors to jointly ensure the safety and effectiveness of the treatment.